Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin

被引:7
作者
Srinivas, N. R. [1 ]
机构
[1] Dr Reddys Inst Life Sci, Univ Hyderabad Campus, Hyderabad 500046, Telangana, India
关键词
pravastatin; simvastatin; pharmacokinetics; peak concentration; AUC; correlation; limited sampling strategy; therapeutic drug monitoring; statins;
D O I
10.1055/s-0035-1549983
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Statins are widely prescribed medicines and are also available in fixed dose combinations with other drugs to treat several chronic ailments. Given the safety issues associated with statins it may be important to assess feasibility of a single time concentration strategy for prediction of exposure (area under the curve; AUC). The peak concentration (C-max) was used to establish relationship with AUC separately for pravastatin and simvastatin using published pharmacokinetic data. The regression equations generated for statins were used to predict the AUC values from various literature references. The fold difference of the observed divided by predicted values along with correlation coefficient (r) were used to judge the feasibility of the single time point approach. Both pravastatin and simvastatin showed excellent correlation of C-max vs. AUC values with r value0.9638 (p<0.001). The fold difference was within 0.5-fold to 2-fold for 220 out of 227 AUC predictions and >81% of the predicted values were in a narrower range of >0.75-fold but <1.5-fold difference. Predicted vs. observed AUC values showed excellent correlation for pravastatin (r=0.9708, n=115; p<0.001) and simvastatin (r=0.9810; n=117; p<0.001) suggesting the utility of C-max for AUC predictions. On the basis of the present work, it is feasible to develop a single concentration time point strategy that coincides with C-max occurrence for both pravastatin and simvastatin from a therapeutic drug monitoring perspective.
引用
收藏
页码:82 / 93
页数:12
相关论文
共 79 条
[31]   Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers [J].
Huang, Ji-Han ;
Wang, Kun ;
Huang, Xiao-Hui ;
He, Ying-Chun ;
Li, Lu-Jin ;
Sheng, Yu-Cheng ;
Yang, Juan ;
Zheng, Qing-Shan .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2013, 38 (02) :123-130
[32]   Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin [J].
Hulskotte, E. G. J. ;
Feng, H. -P. ;
Xuan, F. ;
Gupta, S. ;
van Zutven, M. G. J. A. ;
O'Mara, E. ;
Wagner, J. A. ;
Butterton, J. R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) :2582-2588
[33]   Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs [J].
Ieiri, Ichiro ;
Tsunemitsu, Shyohei ;
Maeda, Kazuya ;
Ando, Yukie ;
Izumi, Noritomo ;
Kimura, Miyuki ;
Yamane, Naoe ;
Okuzono, Tsuyoshi ;
Morishita, Mariko ;
Kotani, Naoki ;
Kanda, Eri ;
Deguchi, Mariko ;
Matsuguma, Kyoko ;
Matsuki, Shunji ;
Hirota, Takeshi ;
Irie, Shin ;
Kusuhara, Hiroyuki ;
Sugiyama, Yuichi .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06) :654-661
[34]   Impact of the SLCOIBI polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin [J].
Igel, Michael ;
Arnold, Katja A. ;
Niemi, Mikko ;
Hofmann, Ute ;
Schwab, Matthias ;
Luetjohann, Dieter ;
von Bergmann, Maus ;
Eichelbaum, Michel ;
Kivisto, Kari T. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (05) :419-426
[35]   Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics [J].
Jin, Seok-Joon ;
Bae, Kyun-Seop ;
Cho, Sang-Heon ;
Jung, Jin-Ah ;
Kim, Unjib ;
Choe, Sangmin ;
Ghim, Jong-Lyul ;
Noh, Yook-Hwan ;
Park, Hyun-Jung ;
Kim, Hee-sun ;
Lim, Hyeong-Seok .
PHARMACEUTICAL RESEARCH, 2014, 31 (07) :1801-1812
[36]   Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations [J].
Kantola, T ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (02) :177-182
[37]   Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin [J].
Kasichayanula, Sreeneeranj ;
Chang, Ming ;
Liu, Xiaoni ;
Shyu, Wen-Chyi ;
Griffen, Steven C. ;
LaCreta, Frank P. ;
Boulton, David W. .
ADVANCES IN THERAPY, 2012, 29 (02) :163-177
[38]   A clinician's guide to statin drug-drug interactions [J].
Kellick, Kenneth A. ;
Bottorff, Michael ;
Toth, Peter P. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) :S30-S46
[39]   No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin [J].
Keskitalo, Jenni E. ;
Kurkinen, Kaisa J. ;
Neuvonen, Mikko ;
Backman, Janne T. ;
Neuvonen, Pertti J. ;
Niemi, Mikko .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (02) :207-213
[40]   Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects [J].
Kim, Kyoung-Ah ;
Park, Pil-Whan ;
Lee, Ock-Je ;
Kang, Dong-Kyun ;
Park, Ji-Young .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (01) :87-93